Cytokeratin 5 (KRT5) Antikörper

Antigen: Cytokeratin 5 (KRT5)

Synonyme: KRT79, CK5, KRT5, K5, Tfip8, Krt2-5, AW146334, 3300001P10Rik, DDD, EBS2, KRT5A

Klonalität: Monoklonal (BV8)

Wirt: Kaninchen

Reaktivität: Human

Applikation: Immunhistochemie (Paraffinschnitte) (IHC (p))

Produktnummer: ABIN303595

Produktbeschreibung

Weitere Bezeichnung: Cytokeratin 5

Immunogen: A synthetic peptide from the c-terminus of human Cytokeratin 5.

Format: Supernatant

Isotyp: IgG  (Passende Sekundärantikörper)

Klon: BV8

Spezifität: This antibody reacts with cytokeratin 5 intermediate filament protein. Basal cells of human epidermis express acidic cytokeratin 14 and basic cytokeratin 5. Cytokeratin 5 is a 58 kD protein, which is closely related to cytokeratin 6. Cytokeratin 5 and 6 are expressed in basal cell epithelioma, basal cells of prostate, urothelium, vagina, squamous cell carcinomas of skin, tongue, epiglottis and rectal-anal region. Cytokeratin 5 can be useful in the distinction of mesotheliomas from most adenocarcinomas.

Anwendungen

Applikationshinweise: This antibody may be diluted to a titer of 1:50 to 1:100 in an ABC method. However, depending on the staining conditions employed, we suggest that final dilution should be determined by the user. We suggest an incubation period of 30-60 minutes at room temperature. However, depending upon the fixation conditions and the staining system employed, optimal incubation should be determined by the user. Formalin fixed paraffin embedded tissue sections require high temperature antigen unmasking with 10 mM citrate buffer, pH 6.0 prior to immunostaining. Positive Control: Mesothilioma

Konzentration: 100ug/ml approximately

Buffer: This antibody is supplied as tissue culture supernatant and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.

Lagerung: Store the antibody at 2-8o c. Do not use it beyond the expiration date stated on the label.

Forschungsgebiet: Zytoskelett, Extrazelluläre Matrix

Beschränkungen: Für Forschungszwecke. Als CE-zertifizierter Antikörper in der Europäischen Union für In Vitro Diagnostik (IVD) zugelassen.

Publikationen

Publikationen: Irvine, McKenna, Jenkinson et al.: "A mutation in the V1 domain of keratin 5 causes epidermolysis bullosa simplex with mottled pigmentation." in: The Journal of investigative dermatology, Vol. 108, Issue 5, pp. 809-10, 1997 (PubMed).